Table 2.
Target | Sequence (5′ to 3′) | bp | R2 | Eff. (%) | Accession | Reference | |
---|---|---|---|---|---|---|---|
β-Actin | F R |
GCTACAGCTTCACCACCACA TCTCCAGGGAGGAAGAGGAT |
123 | 1.000 | 102.4 | XM_013120404.2 | [37] |
Oas1b | F R |
CAGTATGCCCTGGAGCTGC GTACTTGGTGACCAGTTCC |
111 | 0.999 | 103.5 | XM_013119795.2 | This study |
Ifng | F R |
TGTTGCTCTGCCTCACTCAGG AAGACGAGGTCCCCTCCATTC |
130 | 1.000 | 104.2 | AF034482.1 | [41] |
Tnf | F R |
TGAGCCATCGTGCCAATG AGCCCGTCTGCTGGTATCAC |
79 | 0.998 | 97.7 | XM_005086799.3 | [41] |
Tgfb | F R |
TGTGTGCGGCAGCTGTACA TGGGCTCGTGAATCCACTTC |
63 | 1.000 | 100.7 | XM_013125593.2 | [29] |
IL6 | F R |
CCTGAAAGCACTTGAAGAATTCC GGTATGCTAAGGCACAGCACACT |
78 | 1.000 | 112.4 | XM_005087110.2 | [29] |
IL10 | F R |
GGTTGCCAAACCTTATCAGAAATG TTCACCTGTTCCACAGCCTTG |
194 | 1.000 | 99.5 | XM_021232886.1 | [41] |
MODV-NS5 | F R |
CCAGGACAAGTCATGTGGTAGC TCCCAAAGATGTTCCTCACCTT |
101 | 0.998 | 107.5 | NC_003635.1 | [39] |